Biomea goes for $125M offering after early diabetes data nearly doubled stock price
Basking in record-high stock prices thanks to early data in type 2 diabetes, Biomea Fusion is out to raise $125 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
